Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05163548 · ClinicalTrials.gov registry record · NA
PerQseal®+ Early Feasibility Study
A NA study, sponsored by Vivasure Medical Limited.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
NCT05163548 is a NA study that has completed, run by Vivasure Medical Limited. The registered enrollment target is 15 participants.
The verdict
NCT05163548, a NA study, has completed, sponsored by Vivasure Medical Limited.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
Study Summary
The objective of this Early Feasibility Study (EFS) is to evaluate the initial safety and preliminary effectiveness of the PerQseal®+ VCD in a small number of subjects when used to achieve hemostasis of common femoral arteriotomies created by 14 to 22 F sheaths (arteriotomy up to 26 F) in subjects undergoing Percutaneous Transcatheter procedures.
Interventions
- DEVICE PerQseal Plus Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2022-07-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05163548
The ClinicalTrials.gov registry entry for NCT05163548 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vivasure Medical Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PerQseal Plus Device is the first listed.
NCT05163548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05163548 about?
NCT05163548 is a clinical study titled "PerQseal®+ Early Feasibility Study". The objective of this Early Feasibility Study (EFS) is to evaluate the initial safety and preliminary effectiveness of the PerQseal®+ VCD in a small number of subjects when used to achieve hemostasis of common femoral arteriotomies created by 14 to 22 F sheaths (arteriotomy up to 26 F) in subjects u...
What is the current status of trial NCT05163548?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2022-03-08. Estimated completion is 2022-07-07.
What interventions are being tested in trial NCT05163548?
The interventions under investigation include: PerQseal Plus Device (DEVICE).
Who is sponsoring clinical trial NCT05163548?
This trial is sponsored by Vivasure Medical Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.